James Harrison

Former Wall Street Professional | Growth Investor |
Spotting opportunities before they become obvious
True wealth lies in early-stage investments.

[James Harrison @JamesHarrisonN3]

$KARD +1.70%
My prediction of the uptrend was absolutely correct—we are currently in an uptrend. Want to know the best selling price?
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#KARD
#Stocks
#StockMarket
#AIStocks

[James Harrison @JamesHarrisonN3]

$KARD (Want to profit from the stock market more easily? Click the number in my profile to add me on WhatsApp and send me a message.)
Kardigan is an interesting biotech stock because it's targeting a massive healthcare market with three experimental drugs focused on cardiovascular disease.
The latest results show a company moving into a critical stage of development.
In Q2 2026, Kardigan reported a net loss of $116.2 million, compared with $57.4 million a year earlier. R&D expenses increased to $56.4 million as the company advanced its clinical programs.
The good news? Kardigan ended June with approximately $660.7 million in cash, cash equivalents, and investments following its IPO.
Here's the key distinction: the company has substantial funding to advance its pipeline, but it still needs clinical data to prove that its drug candidates can become successful treatments.
That's the bull case.
Kardigan is developing three key programs:
Danicamtiv: Targeting genetic dilated cardiomyopathy, a condition that can lead to heart failure.
Ataciguat: Being studied as a potential treatment for calcific aortic valve stenosis.
Tonlamarsen: Being evaluated for blood pressure management in acute severe hypertension.
Management expects important clinical data from all three programs in the first half of 2027. Those results could significantly influence how investors value the company.
But there are real risks.
Kardigan has no approved commercial products generating sales. Its business depends on clinical development, and increasing R&D spending means cash will continue to be used as trials progress.
What could move $KARD higher?
Positive clinical data across its three drug programs
Progress toward Phase 3 development and potential regulatory approval
Evidence that its treatments can deliver meaningful clinical benefits
Clear milestones toward commercialization
Strong cash management that supports development without excessive dilution
What could go wrong?
Clinical trials fail to meet their primary endpoints
Safety issues or regulatory delays slow development
R&D expenses rise faster than expected
Future financing becomes necessary
The stock's valuation already reflects optimistic clinical outcomes
My take: $KARD is a high-risk biotech opportunity with meaningful upside potential, but the investment thesis remains heavily dependent on clinical results.
The question isn't whether cardiovascular disease represents a large market. It's whether Kardigan can develop safe, effective medicines that make a meaningful difference for patients.

Watch clinical data, trial timelines, cash burn, and regulatory progress. In biotech, a strong balance sheet buys time, but only successful clinical results can validate the pipeline.

#KARD #Kardigan #BiotechStocks #CardiovascularHealth #HealthcareInvesting #GrowthStocks #LongTermInvesting

[James Harrison @JamesHarrisonN3]

$SFIX +7.95%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#SFIX
#Stocks
#QQQ
#AIStocks

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $S***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

Want to profit from the stock market with greater ease? The WhatsApp group is now open!
Click the link to join quickly:
https://t.co/BmHSyP4deV
Alternatively, visit my WhatsApp profile, add me as a contact, and send a message; I will get back to you as soon as possible.
In the community, we will provide insights on:
Stocks worth watching
Key price levels and market positioning
Daily market analysis
WhatsApp community—spots are limited.
Today is your last chance to seize this opportunity. Act now!
Follow me or send a private message, and I’ll provide the details on how to join the community.
#Stocks
#AIStocks
#NVDA

[James Harrison @JamesHarrisonN3]

$KARD +1.70%
My prediction of the uptrend was absolutely correct—we are currently in an uptrend. Want to know the best selling price?
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#KARD
#Stocks
#StockMarket
#AIStocks

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $S***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$KARD (Want to profit from the stock market more easily? Click the number in my profile to add me on WhatsApp and send me a message.)
Kardigan is an interesting biotech stock because it's targeting a massive healthcare market with three experimental drugs focused on cardiovascular disease.
The latest results show a company moving into a critical stage of development.
In Q2 2026, Kardigan reported a net loss of $116.2 million, compared with $57.4 million a year earlier. R&D expenses increased to $56.4 million as the company advanced its clinical programs.
The good news? Kardigan ended June with approximately $660.7 million in cash, cash equivalents, and investments following its IPO.
Here's the key distinction: the company has substantial funding to advance its pipeline, but it still needs clinical data to prove that its drug candidates can become successful treatments.
That's the bull case.
Kardigan is developing three key programs:
Danicamtiv: Targeting genetic dilated cardiomyopathy, a condition that can lead to heart failure.
Ataciguat: Being studied as a potential treatment for calcific aortic valve stenosis.
Tonlamarsen: Being evaluated for blood pressure management in acute severe hypertension.
Management expects important clinical data from all three programs in the first half of 2027. Those results could significantly influence how investors value the company.
But there are real risks.
Kardigan has no approved commercial products generating sales. Its business depends on clinical development, and increasing R&D spending means cash will continue to be used as trials progress.
What could move $KARD higher?
Positive clinical data across its three drug programs
Progress toward Phase 3 development and potential regulatory approval
Evidence that its treatments can deliver meaningful clinical benefits
Clear milestones toward commercialization
Strong cash management that supports development without excessive dilution
What could go wrong?
Clinical trials fail to meet their primary endpoints
Safety issues or regulatory delays slow development
R&D expenses rise faster than expected
Future financing becomes necessary
The stock's valuation already reflects optimistic clinical outcomes
My take: $KARD is a high-risk biotech opportunity with meaningful upside potential, but the investment thesis remains heavily dependent on clinical results.
The question isn't whether cardiovascular disease represents a large market. It's whether Kardigan can develop safe, effective medicines that make a meaningful difference for patients.

Watch clinical data, trial timelines, cash burn, and regulatory progress. In biotech, a strong balance sheet buys time, but only successful clinical results can validate the pipeline.

#KARD #Kardigan #BiotechStocks #CardiovascularHealth #HealthcareInvesting #GrowthStocks #LongTermInvesting

[James Harrison @JamesHarrisonN3]

$KARD (Want to profit from the stock market more easily? Click the number in my profile to add me on WhatsApp and send me a message.)
Kardigan is an interesting biotech stock because it's targeting a massive healthcare market with three experimental drugs focused on cardiovascular disease.
The latest results show a company moving into a critical stage of development.
In Q2 2026, Kardigan reported a net loss of $116.2 million, compared with $57.4 million a year earlier. R&D expenses increased to $56.4 million as the company advanced its clinical programs.
The good news? Kardigan ended June with approximately $660.7 million in cash, cash equivalents, and investments following its IPO.
Here's the key distinction: the company has substantial funding to advance its pipeline, but it still needs clinical data to prove that its drug candidates can become successful treatments.
That's the bull case.
Kardigan is developing three key programs:
Danicamtiv: Targeting genetic dilated cardiomyopathy, a condition that can lead to heart failure.
Ataciguat: Being studied as a potential treatment for calcific aortic valve stenosis.
Tonlamarsen: Being evaluated for blood pressure management in acute severe hypertension.
Management expects important clinical data from all three programs in the first half of 2027. Those results could significantly influence how investors value the company.
But there are real risks.
Kardigan has no approved commercial products generating sales. Its business depends on clinical development, and increasing R&D spending means cash will continue to be used as trials progress.
What could move $KARD higher?
Positive clinical data across its three drug programs
Progress toward Phase 3 development and potential regulatory approval
Evidence that its treatments can deliver meaningful clinical benefits
Clear milestones toward commercialization
Strong cash management that supports development without excessive dilution
What could go wrong?
Clinical trials fail to meet their primary endpoints
Safety issues or regulatory delays slow development
R&D expenses rise faster than expected
Future financing becomes necessary
The stock's valuation already reflects optimistic clinical outcomes
My take: $KARD is a high-risk biotech opportunity with meaningful upside potential, but the investment thesis remains heavily dependent on clinical results.
The question isn't whether cardiovascular disease represents a large market. It's whether Kardigan can develop safe, effective medicines that make a meaningful difference for patients.

Watch clinical data, trial timelines, cash burn, and regulatory progress. In biotech, a strong balance sheet buys time, but only successful clinical results can validate the pipeline.

#KARD #Kardigan #BiotechStocks #CardiovascularHealth #HealthcareInvesting #GrowthStocks #LongTermInvesting

[James Harrison @JamesHarrisonN3]

Bulls vs. Bears: Who's Right About AI?
The bulls say AI demand is real, earnings are growing, and this selloff could create long-term opportunities.
The bears say valuations got stretched, financing costs are rising, and the market may have priced in too much future growth.
Both sides have a point.
Even strong TSMC earnings haven't been enough to calm the broader AI selloff.
My take: AI isn't necessarily broken. But the easy-money phase of the trade may be getting tested.
The key question isn't whether AI will grow. It's whether today's prices already assume too much.
I'm watching earnings guidance, capital spending, and cash flow—not just revenue growth.

Are we seeing a healthy reset or the start of a bigger correction?

Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#ArtificialIntelligence #AIBoom #TechStocks #StockMarket #EarningsSeason #Investing

[James Harrison @JamesHarrisonN3]

$SCTX +8.63%
Today's closing price confirms the accuracy of my previous predictions regarding this stock's performance.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
Gene-editing names can get interesting when real catalysts hit, but hype alone isn't enough.
I'm looking for verified company updates, clinical milestones, and partnership news before calling this a real opportunity.
Biotech traders: what upcoming catalyst are you watching?

Drop your thesis below. 👇

#SCTX #BiotechStocks #GeneEditing #CatalystWatch #StocksToWatch

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $S***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$SCTX +11.30%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#SCTX
#Stocks
#QQQ
#AIStocks

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $S***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$WFG
West Fraser is tied to lumber, engineered wood, and the broader North American housing market.
If construction demand improves, the setup could get more interesting. But lumber pricing, trade policy, and operating costs can swing the outlook fast.
I'm watching the next earnings update for signs of improving demand and better margins.

Cheap isn't automatically a bargain. The cycle matters.

#WFG #ValueInvesting #LumberStocks #HousingMarket #CyclicalStocks

[James Harrison @JamesHarrisonN3]

$WFG(If you'd like to participate, please click the number on my profile to add me on WhatsApp and send me a message.)
West Fraser Timber is one of the world's largest producers of wood building products, with exposure to lumber, plywood, OSB, and engineered wood.
Here's why the stock is worth watching.
Q2 2026 sales reached $1.434 billion, up from $1.334 billion in Q1. The company still reported a $61 million net loss, but adjusted EBITDA swung to positive $59 million from negative $66 million in the previous quarter.
That's a meaningful sequential improvement.
The bigger opportunity is a potential recovery in North American housing and repair-and-remodel demand. If lumber prices improve and newer, more efficient mills ramp up production, West Fraser could see substantial earnings leverage.
The company also generated $192 million in operating cash flow during Q2 and repaid $148 million in operating loans.
But don't ignore the risks.
Mortgage rates and housing affordability remain major headwinds. Tariffs and trade restrictions can complicate the outlook, while weak lumber prices can quickly push the business back into losses.
The company also needs to manage capital spending carefully while navigating a cyclical market.
The bull case: Housing demand eventually improves, mill efficiency increases, and earnings recover faster than investors expect.
The bear case: Weak construction demand and trade uncertainty keep lumber prices under pressure.
My take: $WFG is a cyclical recovery play, not a predictable earnings-growth stock.

Watch lumber prices, housing starts, mill utilization, and free cash flow.

#WFG #WestFraser #LumberStocks #HousingMarket #CyclicalStocks #ValueInvesting

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $S***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$WFG(If you'd like to participate, please click the number on my profile to add me on WhatsApp and send me a message.)
West Fraser Timber is one of the world's largest producers of wood building products, with exposure to lumber, plywood, OSB, and engineered wood.
Here's why the stock is worth watching.
Q2 2026 sales reached $1.434 billion, up from $1.334 billion in Q1. The company still reported a $61 million net loss, but adjusted EBITDA swung to positive $59 million from negative $66 million in the previous quarter.
That's a meaningful sequential improvement.
The bigger opportunity is a potential recovery in North American housing and repair-and-remodel demand. If lumber prices improve and newer, more efficient mills ramp up production, West Fraser could see substantial earnings leverage.
The company also generated $192 million in operating cash flow during Q2 and repaid $148 million in operating loans.
But don't ignore the risks.
Mortgage rates and housing affordability remain major headwinds. Tariffs and trade restrictions can complicate the outlook, while weak lumber prices can quickly push the business back into losses.
The company also needs to manage capital spending carefully while navigating a cyclical market.
The bull case: Housing demand eventually improves, mill efficiency increases, and earnings recover faster than investors expect.
The bear case: Weak construction demand and trade uncertainty keep lumber prices under pressure.
My take: $WFG is a cyclical recovery play, not a predictable earnings-growth stock.

Watch lumber prices, housing starts, mill utilization, and free cash flow.

#WFG #WestFraser #LumberStocks #HousingMarket #CyclicalStocks #ValueInvesting

[James Harrison @JamesHarrisonN3]

$WFG(If you'd like to participate, please click the number on my profile to add me on WhatsApp and send me a message.)
West Fraser Timber is one of the world's largest producers of wood building products, with exposure to lumber, plywood, OSB, and engineered wood.
Here's why the stock is worth watching.
Q2 2026 sales reached $1.434 billion, up from $1.334 billion in Q1. The company still reported a $61 million net loss, but adjusted EBITDA swung to positive $59 million from negative $66 million in the previous quarter.
That's a meaningful sequential improvement.
The bigger opportunity is a potential recovery in North American housing and repair-and-remodel demand. If lumber prices improve and newer, more efficient mills ramp up production, West Fraser could see substantial earnings leverage.
The company also generated $192 million in operating cash flow during Q2 and repaid $148 million in operating loans.
But don't ignore the risks.
Mortgage rates and housing affordability remain major headwinds. Tariffs and trade restrictions can complicate the outlook, while weak lumber prices can quickly push the business back into losses.
The company also needs to manage capital spending carefully while navigating a cyclical market.
The bull case: Housing demand eventually improves, mill efficiency increases, and earnings recover faster than investors expect.
The bear case: Weak construction demand and trade uncertainty keep lumber prices under pressure.
My take: $WFG is a cyclical recovery play, not a predictable earnings-growth stock.

Watch lumber prices, housing starts, mill utilization, and free cash flow.

#WFG #WestFraser #LumberStocks #HousingMarket #CyclicalStocks #ValueInvesting

[James Harrison @JamesHarrisonN3]

AI DEMAND ISN'T GOING AWAY QUIETLY
ASML just raised its full-year sales outlook, saying demand for advanced chipmaking equipment is so strong that supply could remain tight through 2028.
That's a big signal for the AI infrastructure trade.
My watchlist:
NVDA — AI chip demand
TSM — manufacturing capacity
MU — memory demand and competition
My take: This strengthens the long-term AI demand story, but it doesn't mean every chip stock is a buy at any price.
I'm looking for confirmation across the supply chain.

Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#AIStocks #ASML #Nvidia #Semiconductors #TechStocks #Investing

[James Harrison @JamesHarrisonN3]

Want to profit from the stock market with greater ease? The WhatsApp group is now open!
Click the link to join quickly:
https://t.co/BmHSyP4L4t
Alternatively, visit my WhatsApp profile, add me as a contact, and send a message; I will get back to you as soon as possible.
In the community, we will provide insights on:
Stocks worth watching
Key price levels and market positioning
Daily market analysis
WhatsApp community—spots are limited.
Today is your last chance to seize this opportunity. Act now!
Follow me or send a private message, and I’ll provide the details on how to join the community.
#Stocks
#AIStocks
#NVDA

[James Harrison @JamesHarrisonN3]

$RFAI +10.47%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#RFAI
#Stocks
#QQQ
#AIStocks

[James Harrison @JamesHarrisonN3]

$RFAI +10.47%
Today's closing price confirms the accuracy of my previous predictions regarding this stock's performance.
(If you'd like to participate, please click the number on my profile to add me on WhatsApp and send me a message.)
This is a ticker where I'd want answers before chasing a big move.
What's the actual catalyst? A merger target? A new filing? Or just a thin order book creating oversized price swings
RFAI is still a SPAC, so the deal story matters more than a random green candle.
I'm watching official filings and volume confirmation before making any bullish call.

#RFAI #SPACStocks #SpeculativeStocks #PriceAction #TradingWatchlist

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $R***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$RFAI +10.47%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#RFAI
#Stocks
#QQQ
#AIStocks

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $R***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$GFR +3.00% (Please click the number on my profile to add me on WhatsApp)
My prediction of the uptrend was absolutely correct—we are currently in an uptrend
Greenfire Resources gives investors exposure to Canadian oil sands production.
For this one, I'm watching crude prices, operating costs, production updates, and how much cash the business can generate.
Energy stocks can move quickly when the oil outlook changes, but a rising chart isn't enough on its own.
The key question: Can stronger cash flow support the next leg higher?
#GFR #EnergyStocks #OilStocks #ValueInvesting #Commodities

[James Harrison @JamesHarrisonN3]

$GFR (Please click the number on my profile to add me on WhatsApp)
Greenfire Resources focuses on Canadian oil sands production. Its investment thesis comes down to production efficiency, operating costs, realized oil prices, and how much cash the business can generate through the commodity cycle.
Q2 2026 production averaged approximately 13,607 barrels of bitumen per day. The company also closed its acquisition of Connacher Oil and Gas, expanding its asset base.
That creates an opportunity to improve utilization, integrate operations, and potentially generate more cash from its existing infrastructure.
But acquisitions only create value if the economics work.
Oil price volatility, operating costs, capital requirements, environmental obligations, and integration risks can all affect returns. Investors also need to distinguish production growth from actual free cash flow.
The real catalyst is sustained production and disciplined spending while maintaining a healthy balance sheet.
If the company can execute and oil prices cooperate, the market could reassess its cash-generation potential.
This is a cyclical energy investment—not a guaranteed bargain based on a low share price.
Watch realized pricing, production costs, free cash flow, and debt.

#GFR #GreenfireResources #OilStocks #EnergyInvesting #ValueStocks

[James Harrison @JamesHarrisonN3]

Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $R***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#AIStock

[James Harrison @JamesHarrisonN3]

$GFR (Please click the number on my profile to add me on WhatsApp)
Greenfire Resources focuses on Canadian oil sands production. Its investment thesis comes down to production efficiency, operating costs, realized oil prices, and how much cash the business can generate through the commodity cycle.
Q2 2026 production averaged approximately 13,607 barrels of bitumen per day. The company also closed its acquisition of Connacher Oil and Gas, expanding its asset base.
That creates an opportunity to improve utilization, integrate operations, and potentially generate more cash from its existing infrastructure.
But acquisitions only create value if the economics work.
Oil price volatility, operating costs, capital requirements, environmental obligations, and integration risks can all affect returns. Investors also need to distinguish production growth from actual free cash flow.
The real catalyst is sustained production and disciplined spending while maintaining a healthy balance sheet.
If the company can execute and oil prices cooperate, the market could reassess its cash-generation potential.
This is a cyclical energy investment—not a guaranteed bargain based on a low share price.
Watch realized pricing, production costs, free cash flow, and debt.

#GFR #GreenfireResources #OilStocks #EnergyInvesting #ValueStocks

[James Harrison @JamesHarrisonN3]

$GFR (Please click the number on my profile to add me on WhatsApp)
Greenfire Resources focuses on Canadian oil sands production. Its investment thesis comes down to production efficiency, operating costs, realized oil prices, and how much cash the business can generate through the commodity cycle.
Q2 2026 production averaged approximately 13,607 barrels of bitumen per day. The company also closed its acquisition of Connacher Oil and Gas, expanding its asset base.
That creates an opportunity to improve utilization, integrate operations, and potentially generate more cash from its existing infrastructure.
But acquisitions only create value if the economics work.
Oil price volatility, operating costs, capital requirements, environmental obligations, and integration risks can all affect returns. Investors also need to distinguish production growth from actual free cash flow.
The real catalyst is sustained production and disciplined spending while maintaining a healthy balance sheet.
If the company can execute and oil prices cooperate, the market could reassess its cash-generation potential.
This is a cyclical energy investment—not a guaranteed bargain based on a low share price.
Watch realized pricing, production costs, free cash flow, and debt.

#GFR #GreenfireResources #OilStocks #EnergyInvesting #ValueStocks

[James Harrison @JamesHarrisonN3]

THE HEADLINE ISN'T THE TRADE. THE FOLLOW-THROUGH IS.
Today's biggest market connection:
What's happening: Asian chipmakers are selling off as competition from China and questions about AI spending returns to the spotlight.
Sector to watch: Semiconductors and AI infrastructure.
Watchlist: $NVDA, $AMD, $AVGO, $MU.
What would change my view?
Selling pressure fades and key names reclaim important levels.
Volume improves as prices stabilize.
Company-specific news supports the long-term earnings story.
What would keep me cautious?
More negative guidance.
Continued weakness across global chipmakers.
A breakdown that spreads beyond semiconductors.
My take: This could eventually create opportunities, but a falling stock isn't automatically a bargain. I'm tracking relative strength and earnings visibility before making any bullish call.

Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#Semiconductors #AIStocks #NVDA #AMD #TechStocks #StockCatalysts